Found: 25
Select item for more details and to access through your institution.
Cytotoxic sigma-2 ligands trigger cancer cell death via cholesterol-induced-ER-stress.
- Published in:
- Cell Death & Disease, 2024, v. 15, n. 5, p. 1, doi. 10.1038/s41419-024-06693-8
- By:
- Publication type:
- Article
Adenovirus platform enhances transduction efficiency of human mesenchymal stem cells: An opportunity for cellular carriers of targeted TRAIL-based TR3 biologics in ovarian cancer.
- Published in:
- PLoS ONE, 2017, v. 12, n. 12, p. 1, doi. 10.1371/journal.pone.0190125
- By:
- Publication type:
- Article
Release of host-derived membrane vesicles following pilus-mediated adhesion of Neisseria gonorrhoeae.
- Published in:
- Cellular Microbiology, 2005, v. 7, n. 11, p. 1672, doi. 10.1111/j.1462-5822.2005.00584.x
- By:
- Publication type:
- Article
The Targeted SMAC Mimetic SW IV-134 is a strong enhancer of standard chemotherapy in pancreatic cancer.
- Published in:
- Journal of Experimental & Clinical Cancer Research (17569966), 2017, v. 36, p. 1, doi. 10.1186/s13046-016-0470-4
- By:
- Publication type:
- Article
C-terminal truncations in human 3′-5′ DNA exonuclease TREX1 cause autosomal dominant retinal vasculopathy with cerebral leukodystrophy.
- Published in:
- Nature Genetics, 2007, v. 39, n. 9, p. 1068, doi. 10.1038/ng2082
- By:
- Publication type:
- Article
Targeted pancreatic cancer therapy with the small molecule drug conjugate SW IV-134.
- Published in:
- Molecular Oncology, 2014, v. 8, n. 5, p. 956, doi. 10.1016/j.molonc.2014.03.005
- By:
- Publication type:
- Article
Preclinical Evaluation of an Engineered scFv-Fc Targeting Human CD44.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 12, p. 1, doi. 10.2967/jnumed.120.249557
- By:
- Publication type:
- Article
Preclinical Evaluation of an Engineered scFv-Fc Targeting Human CD44.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 11, p. 1, doi. 10.2967/jnumed.120.249557
- By:
- Publication type:
- Article
Preclinical Evaluation of an Engineered scFv-Fc Targeting Human CD44.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 10, p. 1, doi. 10.2967/jnumed.120.249557
- By:
- Publication type:
- Article
Preclinical Evaluation of an Engineered scFv-Fc Targeting Human CD44.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 9, p. 1, doi. 10.2967/jnumed.120.249557
- By:
- Publication type:
- Article
Preclinical Evaluation of an Engineered scFv-Fc Targeting Human CD44.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 7, p. 1, doi. 10.2967/jnumed.120.249557
- By:
- Publication type:
- Article
Preclinical Evaluation of an Engineered scFv-Fc Targeting Human CD44.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 6, p. 1, doi. 10.2967/jnumed.120.249557
- By:
- Publication type:
- Article
A dual function of NKG2 D ligands in NK-cell activation.
- Published in:
- European Journal of Immunology, 2012, v. 42, n. 9, p. 2452, doi. 10.1002/eji.201141849
- By:
- Publication type:
- Article
Erratum: Membrane-proximal TRAIL species are incapable of inducing short circuit apoptosis signaling: Implications for drug development and basic cytokine biology.
- Published in:
- Scientific Reports, 2016, p. 25217, doi. 10.1038/srep25217
- By:
- Publication type:
- Article
Membrane-proximal TRAIL species are incapable of inducing short circuit apoptosis signaling: Implications for drug development and basic cytokine biology.
- Published in:
- Scientific Reports, 2016, p. 22661, doi. 10.1038/srep22661
- By:
- Publication type:
- Article
The targeted SMAC mimetic SW IV-134 augments platinum-based chemotherapy in pre-clinical models of ovarian cancer.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Novel treatment option for MUC16-positive malignancies with the targeted TRAIL-based fusion protein Meso-TR3.
- Published in:
- BMC Cancer, 2014, v. 14, n. 1, p. 1, doi. 10.1186/1471-2407-14-35
- By:
- Publication type:
- Article
Novel treatment option for MUC16-positive malignancies with the targeted TRAIL-based fusion protein Meso-TR3.
- Published in:
- 2014
- By:
- Publication type:
- journal article
Interleukin-6 is a direct mediator of T cell migration.
- Published in:
- European Journal of Immunology, 2004, v. 34, n. 10, p. 2895, doi. 10.1002/eji.200425237
- By:
- Publication type:
- Article
Lysosomal Membrane Permeabilization is an Early Event in Sigma-2 Receptor Ligand Mediated Cell Death in Pancreatic Cancer.
- Published in:
- Journal of Experimental & Clinical Cancer Research (17569966), 2012, v. 31, n. 1, p. 41, doi. 10.1186/1756-9966-31-41
- By:
- Publication type:
- Article
The novel drug candidate S2/IAPinh improves survival in models of pancreatic and ovarian cancer.
- Published in:
- Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-56928-z
- By:
- Publication type:
- Article
Incorporation of Porcine Adenovirus 4 Fiber Protein Enhances Infectivity of Adenovirus Vector on Dendritic Cells: Implications for Immune-Mediated Cancer Therapy.
- Published in:
- PLoS ONE, 2015, v. 10, n. 5, p. 1, doi. 10.1371/journal.pone.0125851
- By:
- Publication type:
- Article
Sigma-2 receptor agonist derivatives of 1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28) induce cell death via mitochondrial superoxide production and caspase activation in pancreatic cancer.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Conjugation to a SMAC mimetic potentiates sigma-2 ligand induced tumor cell death in ovarian cancer.
- Published in:
- Molecular Cancer, 2014, v. 13, n. 1, p. 1, doi. 10.1186/1476-4598-13-50
- By:
- Publication type:
- Article
The novel sigma-2 receptor ligand SW43 stabilizes pancreas cancer progression in combination with gemcitabine.
- Published in:
- Molecular Cancer, 2010, v. 9, p. 298, doi. 10.1186/1476-4598-9-298
- By:
- Publication type:
- Article